side effects of the drugs (n = 21, 6.8%). The compliance of 3HR, 4R and 9H were 85.6%, 100% and 56.3%, respectively. The total number of side effects was 21 (6.8%), 3HR was 15(5.1%, hepatotoxicity 9, drug rash 5, GI trouble 1), and 9H was 7(21.8%, hepatotoxicity 5, drug rash 2) Conclusion: The completion rate of 3HR was relatively good. However, relatively high rate of side effects must be considered when we used 3HR for the treatment of LTBI. were calculated to evaluate the effects of corticosteroids. All analyses were performed by Stata 11.0 software.
The Affiliated Hospital of Inner Mongolia Medical University, China Background and Aims: The purpose of this study was to assess the effects of corticosteroids on mortality, side-effects, and sequelae of patients with tuberculous serositis.
Methods:
We did literature search and meta-analysis on clinical trial studies published up to December 2017 from databases of the Cochrane Infectious Diseases Group Trials Register, the Cochrane Central Register of Controlled Trials, Medline, Embase, and Web of Knowledge databases. Combined relative risk (RR) and 95% confidence intervals (95% CIs) were calculated to evaluate the effects of corticosteroids. All analyses were performed by Stata 11.0 software.
Results:
In total, 21 trials with 2487 participants were included in this report. We found that adjunctive corticosteroids, comparing with antituberculous drugs alone, were significantly associated with low risk of death in patients with TB serositis (RR = 0.83, 95%CI: 0.74-0.94, P = 0.002). However, corticosteroids did not reduce risk of death for HIV-positive TB serositis patients (RR = 0.87, 95%CI: 0.69-1.10, P = 0.246). The incidence of sequelae was significantly lower in corticosteroid group comparing with placebo group (RR = 0.72, 95% CI 0.61-0.87, P < 0.001).
Conclusion: Adjuvant corticosteroids could be effective in reducing mortality and sequelae of TB serositis. Further large placebo controlled trials are required to give more evidences for adjunctive steroid treatment in TB serositis. Background and Aims: Non-tuberculosis mycobacteria (NTM) infection was increasing all over the world. NTM culture rate was also increased up to more than 50% in Chest Hospital TB Laboratory in Taiwan. AFB stain and Mycobacteria Culture of sputum was the guidance of MDR-TB treatment. The result will be confused by NTM colonization and infection. (66/198) had no species identification. Among the colonization, the most common pathogen was MAC (27/86), Mycobacteria abscessus (21/86) , Mycobacterium fortuitum (17/86). Among the infection, the most common pathogen was Mycobacterium abscessus (27/46), Mycobacteria abscessus (10/46) , MAC(3/46). The mean time of first NTM culture was 6.5 months. 43.9% (87/198) of NTM growth was beyond 6th month of MDRTB treatment. There was no CXR deterioration when the NTM was grew. There was no special risk factors among NTM colonization, infection and non NTM group. There was also no difference in MDRTB treatment success rate.
Conclusion: NTM colonization or infection was very common
(52.4%) during MDRTB treatment. NTM would be encountered during the whole course of MDRTB treatment especially over 6 months after MDRTB treatment. Mycobacteium species identification was very important if we use Mycobacterium culture as the guide of MDRTB treatment. Results: There were 14 patients included in the study. Majority of patients were Suspect HIV AIDS patient SHAP 80% , PHAP Positive HIV AIDS 20% , all males, equally distributed at an age range of 19-29 yo = 50% and 30-39 years old = 50% . Most resided in the provinces outside
